Inhibition of GLUT1 by the specific inhibitor WZB117 significantly increases the sensitivity of 5-FU-resistant cells to chemotherapeutic agents (Figure 2), providing an additional therapeutic option for patients with 5-FU-resistant colon cancer (113). Here, SLC2A1 is linked to malignant colon neoplasm.